Answers are grounded in this paper and cite their sources.
Introduction: Kidney transplantation improves outcomes in end-stage renal disease but increases malignancy risk due to immunosuppression, with renal cell carcinoma (RCC) is 10–30 times more common. Early-onset RCC with rapid metastasis is rare, posing screening and treatment challenges. Case presentation: A 63-year-old man, 10 months post-kidney transplant, developed a 15 × 16 mm native-kidney clear cell RCC (pT1a) that was treated with laparoscopic nephrectomy. Three months later, pulmonary metastasis with pleural effusion was confirmed. Pazopanib (800 mg/day) and thoracoscopic adhesiolysis achieved a partial response. Clinical discussion: The presence of sarcomatoid differentiation in the metastasis underscores the aggressive potential of even small RCCs. The patient’s subsequent management with targeted therapy (pazopanib and everolimus) and video-assisted thoracoscopic surgery (VATS) demonstrated a positive clinical response, highlighting the efficacy of a multidisciplinary approach. Conclusion: Routine post-transplant surveillance and tailored therapies (tyrosine kinase inhibitors and mechanistic target of rapamycin inhibitors) are critical. Multidisciplinary care and biomarkers may improve outcomes.
No takes yet. Share an insight, caveat, or question.
Vũ et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: